These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 31326719)

  • 21. [Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis].
    Hong C; Mei T; Wang J
    Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):837-846. PubMed ID: 27978869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer.
    Pujol JL; Pirker R; Lynch TJ; Butts CA; Rosell R; Shepherd FA; Vansteenkiste J; O'Byrne KJ; de Blas B; Heighway J; von Heydebreck A; Thatcher N
    Lung Cancer; 2014 Feb; 83(2):211-8. PubMed ID: 24332319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-agent versus combination chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer and performance status 2: a literature-based meta-analysis of randomized studies.
    Mörth C; Valachis A
    Lung Cancer; 2014 Jun; 84(3):209-14. PubMed ID: 24702946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials.
    Rajeswaran A; Trojan A; Burnand B; Giannelli M
    Lung Cancer; 2008 Jan; 59(1):1-11. PubMed ID: 17720276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Systematic review and Meta-analysis of Shenqi Fuzheng injection combined with first-line chemotherapy for non-small cell lung cancer].
    Hao TT; Xie YM; Liao X; Wang J
    Zhongguo Zhong Yao Za Zhi; 2015 Oct; 40(20):4094-107. PubMed ID: 27062833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer.
    Hotta K; Matsuo K; Ueoka H; Kiura K; Tabata M; Tanimoto M
    J Clin Oncol; 2004 Oct; 22(19):3852-9. PubMed ID: 15326195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non-small-cell lung cancer: a meta-analysis of 14 randomized controlled trials.
    Li X; Wang H; Lin W; Xu Q
    Curr Med Res Opin; 2014 Nov; 30(11):2295-304. PubMed ID: 24701984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].
    Langer F; Helsberg K; Schütte WH; Leschinger MI
    Onkologie; 2005 Mar; 28 Suppl 1():1-28. PubMed ID: 15802886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: a meta-analysis.
    Des Guetz G; Uzzan B; Nicolas P; Valeyre D; Sebbane G; Morere JF
    Crit Rev Oncol Hematol; 2012 Dec; 84(3):340-9. PubMed ID: 22534083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Taxane-platinum combinations in advanced non-small cell lung cancer: a review.
    Rigas JR
    Oncologist; 2004; 9 Suppl 2():16-23. PubMed ID: 15161987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meta-analysis of seven randomized control trials to assess the efficacy and toxicity of combining EGFR-TKI with chemotherapy for patients with advanced NSCLC who failed first-line treatment.
    Xiao BK; Yang JY; Dong JX; Ji ZS; Si HY; Wang WL; Huang RQ
    Asian Pac J Cancer Prev; 2015; 16(7):2915-21. PubMed ID: 25854383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Meta-analysis on effectiveness and safety of traditional Chinese medicine combined with first-generation EGFR-TKI in treating advanced non-small cell lung cancer].
    He W; Cheng M
    Zhongguo Zhong Yao Za Zhi; 2017 Jul; 42(13):2591-2598. PubMed ID: 28840704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Injectable Chinese herbal formula Kang'ai for nonsmall cell lung cancer: Trial sequential analysis of 2,259 participants from 31 randomized controlled trials.
    He XR; Han SY; Li PP
    J Cancer Res Ther; 2016; 12(2):735-43. PubMed ID: 27461643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.
    Qi WX; Shen Z; Yao Y
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):99-106. PubMed ID: 21607554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical efficacy and safety of CIK plus radiotherapy for lung cancer: A meta-analysis of 16 randomized controlled trials.
    Xiao Z; Wang CQ; Zhou MH; Li NN; Liu SY; He YJ; Wang YZ; Feng JH; Yao XS; Chen L; Ma B; Yu S; Zeng XT; Li CW; Ding J
    Int Immunopharmacol; 2018 Aug; 61():363-375. PubMed ID: 29945024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-analysis of response, toxicity, and survival.
    Lilenbaum RC; Langenberg P; Dickersin K
    Cancer; 1998 Jan; 82(1):116-26. PubMed ID: 9428487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline.
    Noble J; Ellis PM; Mackay JA; Evans WK;
    J Thorac Oncol; 2006 Nov; 1(9):1042-58. PubMed ID: 17409993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B; Chen H; Shen J; Ye M
    Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A meta-analysis: Evaluation of safety and efficacy of the epidermal growth factor receptor-tyrosine kinase inhibitor monotherapy versus platinum-based doublets chemotherapy in East Asia.
    Zhang XF; De-Sheng LV; Li M; Sun GE; Liu CH
    Indian J Cancer; 2017; 54(1):104-114. PubMed ID: 29199672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can Aidi injection improve overall survival in patients with non-small cell lung cancer? A systematic review and meta-analysis of 25 randomized controlled trials.
    Xiao Z; Wang C; Zhou R; Hu S; Yi N; Feng J; Zhou M; Liu S; Chen L; Ding J; Gong Q; Tang F; Li X
    Complement Ther Med; 2018 Apr; 37():50-60. PubMed ID: 29609937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.